<DOC>
	<DOCNO>NCT02055976</DOCNO>
	<brief_summary>The purpose study evaluate low density lipoprotein cholesterol ( LDL-C ) lower effect Bococizumab ( PF-04950615 ; RN316 ) administer subcutaneously every two week ( Q14D ) hypercholesterolemic Japanese subject whose LDL-C control stable dose atorvastatin , naïve treatment lipid lower drug whose LDL-C control .</brief_summary>
	<brief_title>Dose Ranging Study Of Bococizumab ( PF-04950615 ; RN316 ) In Hypercholesterolemic Japanese Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hypercholesterolemia</mesh_term>
	<mesh_term>Atorvastatin Calcium</mesh_term>
	<mesh_term>Ezetimibe</mesh_term>
	<criteria>Subjects whose LDLC control stable dose atorvastatin ( Population A ) . Subjects naïve treatment lipid lower drug whose LDLC control ( Population B ) . Severe acute chronic medical psychiatric condition laboratory abnormality . Pregnant female ; breastfeed female ; male females childbearing potential ; male females childbearing potential unwilling unable use highly effective method contraception . Subjects administer prior expose PF04950615 and/or antibody target PCSK9 .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>PF-04950615</keyword>
	<keyword>Japan</keyword>
</DOC>